Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial) - Report - MDSpire
Advertisement
Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)
Clinical Report: Identification and Assessment of Hypermethylated Gene Markers
Overview
This study identifies hypermethylated gene markers in cervical samples that may aid in the detection of endometrial cancer.
Background
Endometrial cancer is the most common gynecological cancer, with rising incidence rates globally. Current diagnostic methods, including transvaginal ultrasound and biopsy, have limitations in sensitivity and specificity, leading to a need for more effective noninvasive screening techniques. The exploration of DNA methylation as a diagnostic tool presents a promising avenue for early detection.
Data Highlights
Marker
AUC (Training Cohort)
Sensitivity (Validation Set)
Specificity (Validation Set)
CDO1
0.93
94.6%
92.8%
CELF4
0.89
NEFM
0.91
Key Findings
Eleven hypermethylated genes were evaluated for their association with endometrial cancer.
The highest AUC values for detecting endometrial cancer were 0.93, 0.91, and 0.89 for CDO1, NEFM, and CELF4, respectively.
The combined methylation markers achieved a sensitivity of 94.6% and specificity of 92.8% in the validation cohort.
Integration of endometrial thickness from transvaginal ultrasound slightly improved diagnostic specificity.
Clinical Implications
The study presents cervical cytological DNA methylation assays as a method for detecting endometrial cancer.
Conclusion
Hypermethylated gene markers in cervical samples represent a promising approach for the noninvasive detection of endometrial cancer, potentially improving early diagnosis and patient outcomes.
